Matthias Holdhoff

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Controversies in the adjuvant therapy of high-grade gliomas
    Matthias Holdhoff
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Oncologist 16:351-8. 2011
  2. doi request reprint Blood-based biomarkers for malignant gliomas
    Matthias Holdhoff
    Brain Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, Suite 1M16, Baltimore, MD 21287, USA
    J Neurooncol 113:345-52. 2013
  3. doi request reprint Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas
    Matthias Holdhoff
    Brain Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    J Neurooncol 110:279-85. 2012
  4. doi request reprint Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
    Matthias Holdhoff
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 1 M 16 1550 Orleans Street, Baltimore, MD, 21231, USA
    J Neurooncol 97:241-5. 2010
  5. pmc Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas
    Hatim Husain
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, 1M 16, Baltimore, MD, 21287, USA
    J Neurooncol 109:123-7. 2012
  6. doi request reprint Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma
    Jian He
    Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Neurooncol 114:275-9. 2013
  7. pmc Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
    Yuchen Jiao
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, The Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Oncotarget 3:709-22. 2012
  8. pmc Systemic use of tumor necrosis factor alpha as an anticancer agent
    Nicholas J Roberts
    Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD 21231, USA
    Oncotarget 2:739-51. 2011

Collaborators

Detail Information

Publications8

  1. pmc Controversies in the adjuvant therapy of high-grade gliomas
    Matthias Holdhoff
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Oncologist 16:351-8. 2011
    ..be extrapolated to patients aged >70 and to patients with lower grade gliomas? and (d) How should novel therapeutic approaches be added to radiation and temozolomide in clinical trials for patients with newly diagnosed glioblastoma?..
  2. doi request reprint Blood-based biomarkers for malignant gliomas
    Matthias Holdhoff
    Brain Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, Suite 1M16, Baltimore, MD 21287, USA
    J Neurooncol 113:345-52. 2013
    ....
  3. doi request reprint Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas
    Matthias Holdhoff
    Brain Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    J Neurooncol 110:279-85. 2012
    ..Molecular markers that are likely to affect patient care should be ordered with the goal to maximize benefit for patients and to avoid non-actionable results and additional costs...
  4. doi request reprint Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
    Matthias Holdhoff
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 1 M 16 1550 Orleans Street, Baltimore, MD, 21231, USA
    J Neurooncol 97:241-5. 2010
    ....
  5. pmc Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas
    Hatim Husain
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, 1M 16, Baltimore, MD, 21287, USA
    J Neurooncol 109:123-7. 2012
    ..GFAP remains a potentially informative plasma biomarker for gliomas. Longitudinal studies are required to correlate pGFAP levels with patient outcomes...
  6. doi request reprint Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma
    Jian He
    Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Neurooncol 114:275-9. 2013
    ..Alternative strategies to develop circulating biomarkers for PCNSL patients need to be explored. ..
  7. pmc Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
    Yuchen Jiao
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, The Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Oncotarget 3:709-22. 2012
    ....
  8. pmc Systemic use of tumor necrosis factor alpha as an anticancer agent
    Nicholas J Roberts
    Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD 21231, USA
    Oncotarget 2:739-51. 2011
    ..Also discussed, based on recent preclinical data, is a potential future role of systemic TNF-α in combination with liposomal chemotherapy to facilitate increased drug uptake into tumors...